Literature DB >> 30803088

Evaluation of a noncanonical Cys40-Cys55 disulfide linkage for stabilization of single-domain antibodies.

Dae Young Kim1, Hiba Kandalaft1, Greg Hussack1, Shalini Raphael1, Wen Ding1, John F Kelly1, Kevin A Henry1, Jamshid Tanha1,2.   

Abstract

Incorporation of noncanonical disulfide linkages into single-domain antibodies (sdAbs) has been shown to enhance thermostability and other properties. Here, we evaluated the effects of introducing a novel disulfide linkage formed between Cys residues at IMGT positions 40 and 55 on the melting temperatures (T m s), reversibility of thermal unfolding, solubility, and antigen-binding affinities of three types of sdAbs (VH H, VH , and VL domains). The Cys40-Cys55 disulfide linkage was tolerated by 9/9 VH Hs, 12/12 VH s, and 2/11 VL s tested and its formation was confirmed by mass spectrometry. Using circular dichroism, we found that the Cys40-Cys55 disulfide linkage increased sdAb T m by an average of 10.0°C (range: 0-21.8°C). However, enhanced thermostability came at the cost of a partial loss of refolding ability upon thermal denaturation as well as, for some sdAbs, significantly decreased solubility and antigen-binding affinity. Thus, Cys40/Cys55 can be added to the panel of known locations for introducing stabilizing noncanonical disulfide linkages into antibody variable domains, although its effects should be tested empirically for individual sdAbs.
© 2019 The Protein Society.

Entities:  

Keywords:  disulfide linkage; protein engineering; single-domain antibody; thermostability

Mesh:

Substances:

Year:  2019        PMID: 30803088      PMCID: PMC6459990          DOI: 10.1002/pro.3595

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  32 in total

Review 1.  Bioequivalence and the immunogenicity of biopharmaceuticals.

Authors:  Huub Schellekens
Journal:  Nat Rev Drug Discov       Date:  2002-06       Impact factor: 84.694

2.  Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains.

Authors:  Pierre A Barthelemy; Helga Raab; Brent A Appleton; Christopher J Bond; Ping Wu; Christian Wiesmann; Sachdev S Sidhu
Journal:  J Biol Chem       Date:  2007-11-28       Impact factor: 5.157

3.  Stabilization of an immunoglobulin fold domain by an engineered disulfide bond at the buried hydrophobic region.

Authors:  Yoshihisa Hagihara; Shouhei Mine; Koichi Uegaki
Journal:  J Biol Chem       Date:  2007-10-11       Impact factor: 5.157

4.  Improved production of single domain antibodies with two disulfide bonds by co-expression of chaperone proteins in the Escherichia coli periplasm.

Authors:  Lisa C Shriver-Lake; Ellen R Goldman; Daniel Zabetakis; George P Anderson
Journal:  J Immunol Methods       Date:  2017-01-26       Impact factor: 2.303

5.  Single-domain antibodies and their utility.

Authors:  Toya Nath Baral; Roger MacKenzie; Mehdi Arbabi Ghahroudi
Journal:  Curr Protoc Immunol       Date:  2013-11-18

6.  A disulfide-stabilized human VL single-domain antibody library is a source of soluble and highly thermostable binders.

Authors:  Kevin A Henry; Hiba Kandalaft; Michael J Lowden; Martin A Rossotti; Henk van Faassen; Greg Hussack; Yves Durocher; Dae Young Kim; Jamshid Tanha
Journal:  Mol Immunol       Date:  2017-08-15       Impact factor: 4.407

Review 7.  Protein disulfide engineering.

Authors:  Alan A Dombkowski; Kazi Zakia Sultana; Douglas B Craig
Journal:  FEBS Lett       Date:  2013-11-26       Impact factor: 4.124

8.  Rabbit anti-HIV-1 monoclonal antibodies raised by immunization can mimic the antigen-binding modes of antibodies derived from HIV-1-infected humans.

Authors:  Ruimin Pan; Jared M Sampson; Yuxin Chen; Michael Vaine; Shixia Wang; Shan Lu; Xiang-Peng Kong
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

9.  A Rational Engineering Strategy for Designing Protein A-Binding Camelid Single-Domain Antibodies.

Authors:  Kevin A Henry; Traian Sulea; Henk van Faassen; Greg Hussack; Enrico O Purisima; C Roger MacKenzie; Mehdi Arbabi-Ghahroudi
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

10.  Antibody light chain variable domains and their biophysically improved versions for human immunotherapy.

Authors:  Dae Young Kim; Rebecca To; Hiba Kandalaft; Wen Ding; Henk van Faassen; Yan Luo; Joseph D Schrag; Nadereh St-Amant; Mary Hefford; Tomoko Hirama; John F Kelly; Roger MacKenzie; Jamshid Tanha
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

View more
  1 in total

Review 1.  Toward Drug-Like Multispecific Antibodies by Design.

Authors:  Manali S Sawant; Craig N Streu; Lina Wu; Peter M Tessier
Journal:  Int J Mol Sci       Date:  2020-10-12       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.